LEVOCETIRIZINE DIHYDROCHLORIDE tablet

Riik: Ameerika Ühendriigid

keel: inglise

Allikas: NLM (National Library of Medicine)

Toimeaine:

LEVOCETIRIZINE DIHYDROCHLORIDE (UNII: SOD6A38AGA) (LEVOCETIRIZINE - UNII:6U5EA9RT2O)

Saadav alates:

REMEDYREPACK INC.

INN (Rahvusvaheline Nimetus):

LEVOCETIRIZINE DIHYDROCHLORIDE

Koostis:

LEVOCETIRIZINE DIHYDROCHLORIDE 5 mg

Manustamisviis:

ORAL

Retsepti tüüp:

PRESCRIPTION DRUG

Näidustused:

Levocetirizine dihydrochloride tablets are indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older. The use of levocetirizine dihydrochloride tablets are contraindicated in: Patients with known hypersensitivity to levocetirizine or any of the ingredients of levocetirizine dihydrochloride tablets, or to cetirizine. Observed reactions range from urticaria to anaphylaxis [ see Adverse Reactions ( 6.2) ]. Patients with end-stage renal disease (CL CR <10 mL/min) and patients undergoing hemodialysis.  Children 6 months to 11 years of age with impaired renal function Risk Summary Available data from published literature and postmarketing experience with levocetirizine use in pregnant women are insufficient to identify any drug-associated risks of miscarriage, birth defects, or adverse maternal or fetal outcomes. In animal reproduction studies, there was no evid

Toote kokkuvõte:

Levocetirizine dihydrochloride tablets, USP 5 mg are white film coated, scored, round, biconvex tablets debossed with '161' on one side and 'H' on other side. They are supplied in NDC: 70518-0931-00 30 in 1 BOTTLE PLASTIC Storage: Store at 20° to 25° C (68° to 77° F) [see USP Controlled Room Temperature]. Repackaged and Distributed By: Remedy Repack, Inc. 625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762

Volitamisolek:

Abbreviated New Drug Application

Toote omadused

LEVOCETIRIZINE DIHYDROCHLORIDE- LEVOCETIRIZINE DIHYDROCHLORIDE TABLET
REMEDYREPACK INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
LEVOCETIRIZINE DIHYDROCHLORIDE
TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR
LEVOCETIRIZINE DIHYDROCHLORIDE
TABLETS.
LEVOCETIRIZINE DIHYDROCHLORIDE TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 1995
INDICATIONS AND USAGE
Levocetirizine dihydrochloride is a histamine H
-receptor antagonist indicated for:
• The treatment of the uncomplicated skin manifestations of chronic
idiopathic urticaria ( 1.2)
DOSAGE AND ADMINISTRATION
CHRONIC IDIOPATHIC URTICARIA ( 2.2)
• Adults and children 12 years of age and older: 5 mg once daily in
the evening
• Children 6 to 11 years of age: 2.5 mg once daily in the evening
• Renal Impairment
Adjust the dose in patients 12 years of age and older with decreased
renal function ( 12.3)
DOSAGE FORMS AND STRENGTHS
• Immediate release breakable (scored) tablets, 5 mg ( 3)
CONTRAINDICATIONS
• Patients with a known hypersensitivity to levocetirizine or any of
the ingredients of levocetirizine dihydrochloride tablets
or to cetirizine ( 4.1)
• Patients with end-stage renal disease at less than 10 mL/min
creatinine clearance or patients undergoing hemodialysis (
4.2)
• Children 6 months to 11 years of age with renal impairment ( 4.3)
WARNINGS AND PRECAUTIONS
• Avoid engaging in hazardous occupation requiring complete mental
alertness such as driving or operating machinery
when taking levocetirizine dihydrochloride ( 5.1)
• Avoid concurrent use of alcohol or other central nervous system
depressants with levocetirizine dihydrochloride ( 5.1).
• Use with caution in patients with predisposing factors of urinary
retention (e.g. spinal cord lesion, prostatic hyperplasia).
Discontinue levocetirizine dihydrochloride if urinary retention occurs
( 5.2).
ADVERSE REACTIONS
The most common adverse reactions (rate ≥2% and > placebo) were
somnolence, nasopharyngitis,